Hardman & Co Research: Switch to Smart

Against a market backdrop of strong growth in consumer adoption of smart home products, Lightwave's next-generation products are seeing a combination of favourable reviews and accelerating sales. An almost three-fold increase in direct-to-consumer revenue to £1.24m in 2018, from £0.35m in 2017, was followed by an overall revenue growth run rate for the first two months of 2019 that was 25% higher than the 4Q'18 run rate. Led by an experienced new CEO, digital marketing and distribution initiatives are among the management team's highest priorities. The £2.5m fundraising, due to be completed in March 2019, will allow the company to execute on these initiatives.

Please click here for the full report:

https://www.hardmanandco.com/research/corporate-research/switch-to-smart/

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.